Weak fundamental momentum pushes Intec Pharma Ltd. (NTEC) lower
Intec Pharma Ltd. (NASDAQ:NTEC) has a beta value of 0.74 and has seen 975,742 shares traded in the recent trading session. The company, currently valued at $20.05 Million, closed the recent trade at $0.29 per share which meant it lost $0 on the day or 2.19% during that session. The NTEC stock price is -1405.17% off its 52-week high price of $4.365 and 54.48% above the 52-week low of $0.132. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.55 Million shares traded. The 3-month trading volume is 7.97 Million shares.
The consensus among analysts is that Intec Pharma Ltd. (NTEC) is a Hold stock at the moment, with a recommendation rating of 3. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 2 have rated it as a Hold, with no one of them advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.
Sporting 2.91% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 25 when the NTEC stock price touched $0.325 or saw a rise of 10.77%. Year-to-date, Intec Pharma Ltd. shares have moved -42%, while the 5-day performance has seen it change -7.29%. Over the past 30 days, the shares of Intec Pharma Ltd. (NASDAQ:NTEC) have changed -29.27%. Short interest in the company has seen 2.87 Million shares shorted with days to cover at 0.36.
Wall Street analysts have a consensus price target for the stock at $0.2, which means that the shares’ value could jump -31.03% from current levels. The projected low price target is $0.2 while the price target rests at a high of $0.2. In that case, then, we find that the current price level is -31.03% off the targeted high while a plunge would see the stock lose -31.03% from current levels.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest +83.7% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Insiders own 10.19% of the company shares, while shares held by institutions stand at 17.02% with a share float percentage of 18.95%. Investors are also buoyed by the number of investors in a company, with Intec Pharma Ltd. having a total of 32 institutions that hold shares in the company. The top two institutional holders are Meitav Dash Investments Ltd with over 2.42 Million shares worth more than $476.7 Thousand. As of March 30, 2020, Meitav Dash Investments Ltd held 3.49% of shares outstanding.
The other major institutional holder is Adage Capital Partners GP L.L.C., with the holding of over 1.46 Million shares as of March 30, 2020. The firm’s total holdings are worth over $287.62 Thousand and represent 2.11% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are AdvisorShares Trust-AdvisorShares Pure Cannabis ETF and ETF Managers Tr-BlueStar TA-BIGI Tech Israel Technology ETF. As of March 30, 2020, the former fund manager holds about 0.61% shares in the company for having 419353 shares of worth $82.61 Thousand while later fund manager owns 332.46 Thousand shares of worth $65.49 Thousand as of March 30, 2020, which makes it owner of about 0.48% of company’s outstanding stock.
